Cited by 368Medical Imaging Techniques and ApplicationsCancer, Hypoxia, and MetabolismRadiopharmaceutical Chemistry and Applications

The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.

Metabolic Positron Emission Tomography Imaging in Cancer Detection and Therapy Response

Open access

Zhu, Aizhi, Lee, Daniel, Shim, Hyunsuk·2011·Seminars in Oncology

DOI 10.1053/j.seminoncol.2010.11.012PMC PMC3075495

Open this paper in CoChat — free account

Abstract

Positron emission tomography (PET) is a noninvasive imaging technique that provides a functional or metabolic assessment of normal tissue or disease conditions. Fluorine 18-fluorodeoxyglucose PET imaging (FDG-PET) is widely used clinically for tumor imaging due to increased glucose metabolism in most types of tumors, and has been shown to improve the diagnosis and subsequent treatment of cancers. We review its use in cancer diagnosis, staging, restaging, and assessment of response to treatment. In addition, other metabolic PET imaging agents in pre-clinical research or clinical trial stages of development are discussed, including amino acid analogs based on increased protein synthesis, and choline, which is based on increased membrane lipid synthesis. Amino acid analogs and choline are more specific to tumor cells than FDG, so they play an important role in differentiating cancers from benign conditions and in the diagnosis of cancers with low FDG uptake or high background FDG uptake. For decades, researchers have shown that tumors display altered metabolic profiles with elevated uptake of glucose, amino acids, and lipids. This can be used for cancer diagnosis and monitoring of the therapeutic response with excellent signal-to-noise ratios.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.seminoncol.2010.11.012

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Cancer statistics, 2009
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed Tomography
Lardinois, D., Weder, W., Hany, T. F., Kamel, E. M., Korom, S., Seifert, B., von Schulthess, G. K., & Steinert, H. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022136 · Cited by 1,416
Role of amino acid transport and countertransport in nutrition and metabolism.
Christensen, H. N. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.1.43 · Cited by 1,105
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Self-citation
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D. R., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 876
Self-citation
Clinical Applications of PET in Oncology
ROHREN, E. M., Turkington, T. G., & Coleman, R. E. (2004) · Radiology · doi:10.1148/radiol.2312021185 · Cited by 862 · cited 1×
“Although FDG-PET has shown great success in cancer diagnosis and assessment of treatment response, FDG has the following limitations: (1) increased accumulation of FDG in some benign processes, such as infectious and inflammatory lesions that can give false positive results; (2) low sensitivity in well-differentiated…”

Show all 121 references

Sorted by citations

Items 101–200 of 368

Automated detection and classification of tumor histotypes on dynamic PET imaging data through machine-learning driven voxel classification
Bianchetti, G., Taralli, S., Vaccaro, M., Indovina, L., Mattoli, M. V., Capotosti, A., Scolozzi, V., Calcagni, M. L., Giordano, A., Spirito, M. D., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105423 · Cited by 23
Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Jailkhani, N., Clauser, K. R., Mak, H. H., Rickelt, S., Tian, C., Whittaker, C. A., Tanabe, K. K., Purdy, S. R., Carr, S. A., & Hynes, R. O. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1532 · Cited by 22
“18 F-FDG is taken up by metabolically active sites in the organism such as sites of tumors and metastases (35).”
Imaging and monitoring of granzyme B in the immune response
Li, X., Chen, G., Wu, K., Zheng, H., Tian, Z., Xu, Z. Q., Zhao, W., Weng, J., & Min, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1928 · Cited by 21
Super-resolution techniques for biomedical applications and challenges
Shin, M., Seo, M., Lee, K., & Yoon, K. (2024) · Biomedical Engineering Letters · doi:10.1007/s13534-024-00365-4 · Cited by 21
“For example, since cancer cells tend to use more glucose than normal cells, they can be detected with a glucose-based radiotracer [123].”
Vibrational Profiling of Brain Tumors and Cells
Nelson, S. L., Proctor, D. T., Ghasemloonia, A., Lama, S., Zareinia, K., Ahn, Y., Al-Saiedy, M., Green, F. H. Y., Amrein, M., & Sutherland, G. R. (2017) · Theranostics · doi:10.7150/thno.19172 · Cited by 21
“Metabolic characterization of brain tumors may reflect tumor aggressiveness and is important in making effective treatment decisions (25, 26).”
Background
Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines
Stapel, B., Melzer, C., von der Ohe, J., Hillemanns, P., Bleich, S., Kahl, K. G., & Hass, R. (2021) · Scientific Reports · doi:10.1038/s41598-020-80850-9 · Cited by 21
Image-mode performance characterisation of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT)
Hu, Z., Bieniosek, M. F., Ferri, V., Iagaru, A. H., Kovalchuk, N., Han, B., Xing, L., Vitzthum, L. K., Olcott, P. D., Narayanan, M. V., et al. (2022) · British Journal of Radiology · doi:10.1259/bjr.20220387 · Cited by 21
A systematic review and meta‐analysis of predictive and prognostic models for outcome prediction using positron emission tomography radiomics in head and neck squamous cell carcinoma patients
Philip, M. M., Welch, A. E., McKiddie, F. I., & Nath, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6278 · Cited by 21
Integrative analysis of cancer imaging readouts by networks
Dominietto, M. D., Tsinoremas, N. F., & Capobianco, E. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.013 · Cited by 21
“In the context of cancer hallmarks, PET is used to detect the formation of metastasis (Tateishi et al., 2008), to study hypoxia levels (Chitneni et al., 2011) and glucose metabolism (Zhu et al., 2011), to quantify apoptotic cell population (Blankenberg, 2008) and to stage several types of tumors.”
Probing carbohydrate metabolism using hyperpolarized 13C‐labeled molecules
Singh, J., Suh, E. H., Sharma, G., Khemtong, C., Sherry, A. D., & Kovács, Z. Z. (2018) · NMR in Biomedicine · doi:10.1002/nbm.4018 · Cited by 21
“In cancer, (18)F‐FDG can detect changes in metabolic activities well before morphological changes are observed.(42) Thus, (18)F‐FDG has become an extremely valuable tool in the clinic to diagnose and stage tumors and to monitor cancer treatment (Figure 2).”
Biomedical Applications of the Dynamic Nuclear Polarization and Parahydrogen Induced Polarization Techniques for Hyperpolarized 13C MR Imaging
Stewart, N. J., & Matsumoto, S. (2019) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.rev.2019-0094 · Cited by 21
89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma
Poty, S., Mandleywala, K., O’Neill, E. S., Knight, J. C., Cornelissen, B. T., & Lewis, J. S. (2020) · Theranostics · doi:10.7150/thno.44772 · Cited by 22
“responses to treatment through molecular imaging techniques offer the incredible opportunity for early treatment response monitoring when anatomical changes cannot be measured yet [18].”
Background
Characterization of an Orthotopic Rat Model of Glioblastoma Using Multiparametric Magnetic Resonance Imaging and Bioluminescence Imaging
Le, T., Lim, H., Hamilton, A. M., Parkins, K. M., Chen, Y., Scholl, T. J., & Ronald, J. A. (2018) · Tomography · doi:10.18383/j.tom.2018.00012 · Cited by 20
“They used BLI to longitudinally monitor the efficacy of two novel therapies in a brainstem xenograft C6 rat model (60, 61).”
Method
Novel Target Selection for Nuclear Medicine Studies
Lee, S. T., Burvenich, I. J. G., & Scott, A. M. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.06.004 · Cited by 21
Physiological Activity of Spinal Cord in Children
Taralli, S., Leccisotti, L., Mattoli, M. V., Castaldi, P., de Waure, C., Mancuso, A., & Rufini, V. (2015) · Spine · doi:10.1097/brs.0000000000000895 · Cited by 20
The Role of PET in Monitoring Therapy in Fungal Infections
Ankrah, A. O., Klein, H. C., Span, L. F. R., de Vries, E. F. J., Dierckx, R., Sathekge, M. M., & Glaudemans, A. W. J. M. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612824666171213101648 · Cited by 20
“Advances in medicine have resulted in an increased understanding of the molecular basis of diseases; therefore the use of nuclear medicine techniques is becoming more and more relevant in management of disease [1-3].”
Background
Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods
Fathi, M., Taher, H. J., Al-Rubiae, S. J., Yaghoobpoor, S., Bahrami, A., Eshraghi, R., Sadri, H., Anar, M. A., & Gholamrezanezhad, A. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i4.93461 · Cited by 19
“…and some non-neoplastic conditions[104], FDG-PET-CT is invaluable due to its capacity to evaluate the abnormal metabolic activity that occurs before any visible changes in structure, as well as its capability of detecting tiny malignant tumors within structures with normal morphology[105].”
Manganese oxide nanoplatforms for disease diagnosis and treatment: Progress, challenges and opportunities
Poon, K., Gupta, A., Price, W. S., Zreiqat, H., & Singh, G. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215548 · Cited by 19
A multi-instance tumor subtype classification method for small PET datasets using RA-DL attention module guided deep feature extraction with radiomics features
Diao, Z., & Jiang, H. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108461 · Cited by 18
MPGAN: Multi Pareto Generative Adversarial Network for the denoising and quantitative analysis of low-dose PET images of human brain
Fu, Y., Dong, S., Huang, Y., Niu, M., Ni, C., Yu, L., Shi, K., Yao, Z., & Zhuo, C. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103306 · Cited by 18
Towards In Vivo Imaging of Cancer Sialylation
Martínez-Duncker, I., Salinas-Marín, R., & Carlos Martínez-Duncker, R. (2011) · International Journal of Molecular Imaging · doi:10.1155/2011/283497 · Cited by 18
“The association of this effect to malignancy has made FDG an indispensable or at least a very important imaging agent in the diagnosis, staging, restaging, and assessment of treatment in various types of cancer including lung, colorectal, esophageal, stomach, head and neck, thyroid, cervical, ovarian, and breast cance…”
Background
Reliability of 18F-FDG PET Metabolic Parameters Derived Using Simultaneous PET/MRI and Correlation With Prognostic Factors of Invasive Ductal Carcinoma: A Feasibility Study
Jena, A., Taneja, S., Singh, A., Negi, P., Sarin, R., Das, P. K., & Singhal, M. K. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.16.17766 · Cited by 18
Non-radioactive 2-deoxy-2-fluoro-D-glucose inhibits glucose uptake in xenograft tumours and sensitizes HeLa cells to doxorubicin in vitro
Niccoli, S., Boreham, D. R., Phenix, C. P., & Lees, S. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187584 · Cited by 20
Synthesis, characterization and evaluation of 68Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor
Liolios, C. C., Shegani, A., Roupa, I., Kiritsis, C., Makarem, A., Paravatou‐Petsotas, M., Pelecanou, M., Bouziotis, P., Papadopoulos, M. S., Kopka, K., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103855 · Cited by 17
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy
Maresca, K. P., Chen, J., Mathur, D., Giddabasappa, A., Root, A. R., Narula, J., King, L., Schaer, D., Golas, J., Kobylarz, K. A., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01621-0 · Cited by 17
Biomarkers for Use in Monitoring Responses of Nasopharyngeal Carcinoma Cells to Ionizing Radiation
Gao, W., Li, Z.-H., Ho, W., Chan, J. Y. W., & Wong, T. (2012) · Sensors · doi:10.3390/s120708832 · Cited by 17
“(18)F-FDG-PET/CT has been applied in diagnosis, staging, prognosis and monitoring therapy response in a wide variety of cancers including lung cancer, head and neck cancer, brain cancer, lymphoma, oesophageal cancer, prostate cancer, breast cancer, colorectal cancer and pancreatic cancer [56,58].”
Background
Advances in the In Vivo Molecular Imaging of Invasive Aspergillosis
Gunzer, M., Thornton, C. R., & Bézière, N. (2020) · Journal of Fungi · doi:10.3390/jof6040338 · Cited by 16
“The most broadly used tracer for PET imaging is 18F-fluorodeoxyglucose (18F-FDG), which is taken up by cells due to the Warburg effect and is the current gold standard to map tumours or their metastases in cancer patients [48] and can be used for brain activity monitoring [49], inflammation and infection [50–52] and i…”
Method
Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection
Bagga, P., Haris, M., D’Aquilla, K., Wilson, N. E., Marincola, F. M., Schnall, M. D., Hariharan, H., & Reddy, R. D. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1221-9 · Cited by 16
Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis
Barć, K., & Kuźma‐Kozakiewicz, M. (2019) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2019.0013 · Cited by 15
“Cognitive impairment may be absent in the prodromal phase with only behavioural changes, which can lead to an such as clinical guideline, CSF biomarkers, MRI, CT and SPECT [13].”
BackgroundInfluential
Image restoration algorithm incorporating methods to remove noise and blurring from positron emission tomography imaging for Alzheimer's disease diagnosis
Lee, M., Yun, C., Kim, K., & Lee, Y. (2022) · Physica Medica · doi:10.1016/j.ejmp.2022.10.016 · Cited by 15
Preparation and biodistribution of a 99mTc tricarbonyl complex with deoxyglucose dithiocarbamate as a tumor imaging agent for SPECT
Lin, X., Chao, X., Zhang, J., Jin, Z., & Zhang, Y. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.037 · Cited by 15
Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management
Kopytov, S., Sagitova, G. R., Guschin, D. Y., Egorova, V. S., Zvyagin, A. V., & Rzhevskiy, A. S. (2025) · Cancers · doi:10.3390/cancers17152589 · Cited by 17
Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow
Leal, J., Rowe, S. P., Stearns, V., Connolly, R., Vaklavas, C., Liu, M. C., Storniolo, A., Wahl, R., Pomper, M., & Solnes, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1007874 · Cited by 11
“[ 18 F]FDG PET/CT plays a signi ﬁ cant role in detection and management of a variety of oncologic abnormalities (21).”
Background
Tailoring the clinical management of colorectal cancer by 18F-FDG PET/CT
Shi, Y., Wang, M., Zhang, J.-Y., Xiang, Z., Li, C., Zhang, J.-J., & Ma, X.-Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1062704 · Cited by 12
“PET with flourine-18 fluorodeoxyglucose ((18)F-FDG PET/CT, hereafter refers as PET/ CT) not only provides alternations of morphology, but also glycolytic metabolism changes based on glucose uptake, which increasing early diagnostic efficacy and visualize active tumor tissue (12).”
Background
Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy
Das, A., Giuliani, M., & Bezjak, A. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2022.11.007 · Cited by 14
Image based modeling of tumor growth
Meghdadi, N., Soltani, M., Niroomand-Oscuii, H., & Ghalichi, F. (2016) · Australasian Physical & Engineering Sciences in Medicine · doi:10.1007/s13246-016-0475-5 · Cited by 14
Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation
Chung, Y., Yu, C., Chiu, S., Chiu, H., Hsu, S.-T., Wu, C.-R., Yang, C.-L., Hong, J., Yen, T., & Chen, G. T. Y. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04318-3 · Cited by 14
Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging
Altine, B., Gai, Y., Han, N., Jiang, Y., Ji, H., Fang, H., Niyonkuru, A., Bakari, K. H., Arnous, M. M. R., Liu, Q., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00690 · Cited by 14
A Critical Review of PET Tracers Used for Brain Tumor Imaging
Borja, A. J., Hancin, E. C., Raynor, W., Ayubcha, C., Detchou, D. K. E. D., Werner, T. J., Revheim, M.-E. R., & Alavi, A. A. (2021) · PET Clinics · doi:10.1016/j.cpet.2020.12.004 · Cited by 14
Clinical Applications of PET/CT in Oncology
Mahajan, A., & Cook, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-40070-9_18 · Cited by 14
Simultaneous maximuma posteriorilongitudinal PET image reconstruction
Ellis, S., & Reader, A. J. (2017) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aa7b49 · Cited by 14
Molecular imaging biomarkers for cell-based immunotherapies
Haris, M., Bagga, P., Hariharan, H., McGettigan-Croce, B., Johnson, L. A., & Reddy, R. D. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1240-6 · Cited by 13
“Among the molecular imaging techniques, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) imaging of cancer is the most studied modality in oncologic nuclear imaging [33].”
Background
Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(−)-[18F]Fluspidine in Glioblastoma
Toussaint, M., Deuther‐Conrad, W., Kranz, M., Fischer, S., Ludwig, F., Juratli, T. A., Patt, M., Wünsch, B., Schackert, G., Sabri, O., et al. (2020) · Molecules · doi:10.3390/molecules25092170 · Cited by 13
The Role of Genetic Pathways in the Development of Chemoradiation Resistance in Nasopharyngeal Carcinoma (NPC) Patients
Lazim, N. M., Lah, C. I. C., Juhari, W. K. W., Sulong, S., Zilfalil, B. A., & Abdullah, B. (2021) · Genes · doi:10.3390/genes12111835 · Cited by 13
Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications
Ock, C.-Y., Kim, T., Lee, K.-H., Han, S., Im, S., Kim, T.-Y., Bang, Y., & Oh, D. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0504-1 · Cited by 13
“SUV correlates with tumor cell metabolism [21], HER2? AGC would be a more hypermetabolic tumor compared with HER2- AGC on the basis of this analysis.”
Background
Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets
Feng, J., Gao, H., Zhang, Q., Zhou, Y., Li, C., Zhao, S., Hong, L., Yang, J., Hao, S., Hong, W., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2042-9 · Cited by 13
Exploring Cancer Metabolism: Applications of Metabolomics and Metabolic Phenotyping in Cancer Research and Diagnostics
Graça, G., Lau, C. E., & Gonçalves, L. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_19 · Cited by 13
Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography
González-Gómez, R., Pazo-Cid, R., Sarría, L., Morcillo, M. Á., & Schuhmacher, A. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061151 · Cited by 14
“As previously described, [18F]FDG PET imaging present multiple limitations for PDAC diagnosis [90].”
Method
PET Imaging of Metabolism, Perfusion, and Hypoxia
Pantel, A. R., Bae, S.-W., Li, E. J., O’Brien, S. R., & Manning, H. C. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000716 · Cited by 12
A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors
Dantkale, K. S., & Agrawal, M. (2024) · Cureus · doi:10.7759/cureus.52650 · Cited by 13
Bioluminescence Imaging Serves as a Dynamic Marker for Guiding and Assessing Thermal Treatment of Cancer in a Preclinical Model
Au, J. T., González, L., Chen, C., Serganova, I. S., & Fong, Y. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2313-7 · Cited by 12
Association of Fludeoxyglucose F 18–Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence
Sivarajah, S., Isaac, A., Cooper, T., Zhang, H., Puttagunta, L., Abele, J. T., Biron, V. L., Harris, J. R., Seikaly, H. R., & Connell, D. A. O. (2018) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2018.2143 · Cited by 12
“The (18)F-FDGtracer isaradiopharmaceuticalanalogueofglucosemetabolismthat reflectscellularactivityandproliferation.(5) Metabolicvariablesallowforanoninvasiveandquantitativeassessmentof tumorburdenbyanalyzing the3-dimensionaldistributionofactivitybasedonthephotonsemittedbythe labeled tracer.”
Background
Relocation of phosphofructokinases within epithelial cells is a novel event preceding breast cancer recurrence that accurately predicts patient outcomes
Cheung, R. A., Kraft, A. M., & Petty, H. R. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00176.2021 · Cited by 12
Discovery and Design of Radiopharmaceuticals by In silico Methods
Winkler, D. A., Salahinejad, M., & Shiri, F. (2022) · Current Radiopharmaceuticals · doi:10.2174/1874471015666220831091403 · Cited by 11
Encapsulation and retention of chelated-copper inside hydrophobic nanoparticles: Liquid cored nanoparticles show better retention than a solid core formulation
Hervella, P., Parra‐Ortiz, E., & Needham, D. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.02.015 · Cited by 12
A systematic review of the predictive value of 18 F ‐fluoro‐2‐deoxyglucose positron emission tomography on survival in locally advanced rectal cancer after neoadjuvant chemoradiation
Krug, B., Crott, R., Cannière, L. D., D'Hondt, L. A., & Borght, T. V. (2013) · Colorectal Disease · doi:10.1111/codi.12295 · Cited by 11
Prognostic value of [ 18 F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience
Ventura, L., Scarlattei, M., Gnetti, L., Silini, E. M., Rossi, M., Tiseo, M., Sverzellati, N., Bocchialini, G., Musini, L., Balestra, V., et al. (2020) · Tumori Journal · doi:10.1177/0300891620904404 · Cited by 11
Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional
Borgatti, A., Dickerson, E. B., & Lawrence, J. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12554 · Cited by 11
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease
Raimondi, V., Toscani, D., Marchica, V., Burroughs-Garcia, J., Storti, P., & Giuliani, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015402 · Cited by 10
“Another technique of preference is the Positron Emission Tomography (PET)/CT which draws on information from the metabolic activity of tumor cells within the investigated area that uptake a radioactive tracer (14).”
[ 64 Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis
Lee, H. J., Bernau, K., Harr, T. J., Rosenkrans, Z. T., Kessler, G. A., Stott, K., Oler, A. T., Rahar, B., Zhu, T., Medina-Guevara, Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj1444 · Cited by 10
“Positron emission tomography (PET) is a noninvasive imaging technique that allows for monitoring of dynamic metabolic or bio-chemical changes at a molecular level ( 13 ).”
Replenishment of TCA cycle intermediates and long-noncoding RNAs regulation in breast cancer
Zheng, X., Zhang, S., Ma, H., Dong, Y., Zheng, J., Zeng, L., Liu, J., Dai, Y., & Yin, Q. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112321 · Cited by 10
Sensitivity study of voxel‐based PET image comparison to image registration algorithms
Yip, S. S. F., Chen, A. B., Aerts, H. J. W. L., & Berbeco, R. (2014) · Medical Physics · doi:10.1118/1.4898125 · Cited by 10
Failure of MIBG scan to detect metastases in SDHB‐mutated pediatric metastatic pheochromocytoma
Sait, S. F., Pandit-Taskar, N. D., & Modak, S. I. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26549 · Cited by 10
Hypoxia-Mediated In Vivo Tumor Glucose Uptake Measurement and Analysis
Shukla, S. K., Mulder, S. E., & Singh, P. K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7665-2_10 · Cited by 10
Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis
Mititelu, R., Mitoi, A., Mazilu, C., Jinga, M., Radu, F. I., Bucurica, A., Mititelu, T. S., & Bucurica, S. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001863 · Cited by 9
“PET/CT scans are highly effective for early cancer detection as they can identify lesions at a stage when these changes are metabolically present but not yet morphologically visible [35,36].”
In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development
Lindner, J. R., & Morello, M. (2024) · Circulation · doi:10.1161/circulationaha.124.066522 · Cited by 9
Handcrafted vs. Deep Radiomics vs. Fusion vs. Deep Learning: A Comprehensive Review of Machine Learning -Based Cancer Outcome Prediction in PET and SPECT Imaging
Salmanpour, M. R., Mehrnia, S. S., Ghandilu, S. J., Safahi, Z., Falahati, S., Taeb, S., Mousavi, G., Maghsudi, M., Shariftabrizi, A., Hacihaliloglu, I., et al. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-025-01804-z · Cited by 9
Deep learning framework to synthesize high-count preclinical PET images from low-count preclinical PET images
Dutta, K., Liu, Z., Laforest, R. A., Jha, A. K., & Shoghi, K. I. (2022) · SPIE Medical Imaging: Physics of Medical Imaging · doi:10.1117/12.2612729 · Cited by 9
“The quantitative interpretation of PET imaging is important for diagnosis and therapeutic design [3].”
Background
Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters
Gholami, Y. H., Willowson, K. P., & Bailey, D. L. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00479-7 · Cited by 9
Standardized uptake value and metabolic tumor volume measured by 18F FDG PET/CT are sensitive biomarkers for the presence of lymph node metastasis in patients with cervical carcinoma
Vural, G. U., Akkaş, B. E., & Demirel, B. B. (2014) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2013.05.007 · Cited by 9
Involvement of increased p53 expression in the decrease of mitochondrial DNA copy number and increase of SUVmax of FDG-PET scan in esophageal squamous cell carcinoma
Lin, C., Huang, Y.-Y., Pan, S.-C., Cheng, C., Liu, C., Shih, C.-H., Ho, H., Yeh, Y., Chou, T., Lee, M.-Y., et al. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.05.001 · Cited by 9
Development of Novel Analogs of the Monocarboxylate Transporter Ligand FACH and Biological Validation of One Potential Radiotracer for Positron Emission Tomography (PET) Imaging
Sadeghzadeh, M., Wenzel, B., Gündel, D., Deuther‐Conrad, W., Toussaint, M., Moldovan, R., Fischer, S., Ludwig, F., Teodoro, R., Jonnalagadda, S., et al. (2020) · Molecules · doi:10.3390/molecules25102309 · Cited by 9
“Positron emission tomography (PET) is known as a powerful tool for non-invasive molecular detection of early metabolic changes in cancer progression [9].”
Method
Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.
Grega, S. D., Zheng, D. X., & Zheng, Q. (2022) · PubMed Central · Cited by 8
Diastereoselective Synthesis of the Borylated d-Galactose Monosaccharide 3-Boronic-3-Deoxy-d-Galactose and Biological Evaluation in Glycosidase Inhibition and in Cancer for Boron Neutron Capture Therapy (BNCT)
Simone, M. I. (2023) · Molecules · doi:10.3390/molecules28114321 · Cited by 8
“If—as in previous work—these analogues also display a selectivity for cancer cells via exploitation of the Warburg effect [40,41], as FDG does [63,64], then they would become toxic only during the geographically targeted irradiation during BNCT and obliterate almost exclusively cancer cells.”
Background
Biomedical Imaging: Scope for Future Studies and Applications
Anil, S., Vikas, B., Thomas, N. G., & Sweety, V. K. (2025) · Biological and medical physics, biomedical engineering · doi:10.1007/978-981-96-1124-9_14 · Cited by 8
Molecular imaging: The convergence of form and function
Malone, C. D., & Newton, I. G. (2018) · Applied Radiology · doi:10.37549/ar2484 · Cited by 9
C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors
Viswanath, P., Li, Y., & Ronen, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_12 · Cited by 8
Efficacy of convection enhanced delivery of MTX110 (soluble panobinostat) in preclinical Diffuse Intrinsic Pontine Glioma models using metabolic hyperpolarized 13C imaging
Przystal, J. M., Park, I., Zhang, J., Hadaczek, P., Bankiewicz, K. S., Gupta, N. M., Nazarian, J., & Mueller, S. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100021 · Cited by 8
Evaluation of the tumor registration error in biopsy procedures performed under real‐time PET/CT guidance
Fanchon, L. M., Apte, A., Schmidtlein, C. R., Yorke, E. D., Hu, Y., Doğan, S., Hatt, M., Visvikis, D., Humm, J. L., Solomon, S. B., et al. (2017) · Medical Physics · doi:10.1002/mp.12334 · Cited by 8
“Fusion of CT with PET images allows physicians to identify and biopsy a metabolically active lesion before morphologic changes can be observed.(2) In the case of PET/CT guided biopsies the success depends on accurate positioning of the needle relative to the FDG-avid lesion.”
Mechanisms of Metastasis and Cell Mobility – The Role of Metabolism
Gründker, C., Läsche, M., Hellinger, J. W., & Emons, G. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0805-9113 · Cited by 8
Multiple pericardial hematomas: a case report and mini-review in multimodality imaging
Saboe, A., Sanjaya, F., Koesoemah, R. E. A. S., Maryani, E., Kusumawardhani, N. Y., Cool, C. J., & Astuti, A. (2021) · BMC Medical Imaging · doi:10.1186/s12880-021-00617-0 · Cited by 8
“F-fluorodeoxyglucose PET imaging (FDG-PET) is the most established nuclear imaging for malignancy evaluation by showing hypermetabolic activity due to increased glucose metabolism in most tumor types [23, 24].”
Background
Development of 68Ga DOTA-CRH for PET/CT Imaging of ACTH-Dependent Cushing's Disease: Initial Study
Shukla, J., Vatsa, R., Walia, R., Chhabra, A., Rana, N., Singh, H., Kumar, R., & Mittal, B. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4686 · Cited by 10
Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cells
Godfrey, J. T., Riscal, R., Skuli, N., & Simon, M. C. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00280-1 · Cited by 9
“rounding normal tissue due to their enhanced uptake of glucose, commonly observed via fluorodeoxyglucose PET imaging [1].”
Background
Predictive Value of Early-Stage Uptake of 3′-Deoxy-3′-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation
Lin, C., Kume, K., Mori, T., Martinez, M. E., Okazawa, H., & Kiyono, Y. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152983 · Cited by 8
“By being able to show the metabolic and physiologic changes that precede a change in size, PET solved this problem and has been widely used for diagnosing cancer, monitoring therapy response, and planning radiotherapy (8,9).”
Method
Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma
Alkhawtani, R. H. M., Noordzij, W., Glaudemans, A. W. J. M., van Rijn, R. S., van der Galiën, H. T., Balink, H., Nijland, M., Adams, H. J. A., Huls, G. A., van Meerten, T., et al. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000840 · Cited by 8
Role of animal research in human malignancies
Khan, A. Q., Siveen, K. S., Prabhu, K. S., Kuttikrishnan, S., Akhtar, S., Shanmugakonar, M., Al‐Naemi, H. A., Haris, M., & Shahab Uddin, M. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00003-9 · Cited by 8
Targeting Signalling Cross-Talk between Cancer Cells and Cancer-Associated Fibroblast through Monocarboxylate Transporters in Head and Neck Cancer
Chandel, V., & Kumar, D. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200721135230 · Cited by 8
Spatial modeling of prostate cancer metabolic gene expression reveals extensive heterogeneity and selective vulnerabilitiesPreprint
Wang, Y., Ma, S., & Ruzzo, W. L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/719294 · Cited by 9
Old Discovery Leading to New Era: Metabolic Imaging of Cancer with Deuterium MRI
Ding, H., Haroon, A., Wan, S., Niendorf, T., & Adeleke, S. M. (2022) · Magnetochemistry · doi:10.3390/magnetochemistry9010006 · Cited by 7
“Labelled-pyruvate can also be metabolized to [3,3-2 H]-lactate anaerobically, catalysed by lactate dehydrogenase.”
Background
The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC
Agüloğlu, N., Aksu, A., Unat, D. S., & Akyol, M. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001625 · Cited by 7
Comparative assessment of the diagnostic efficacy of [18F]AlF-NOTA-FAPI-04 and [18F]FDG PET/CT imaging for detecting postoperative recurrence in gastric cancer patients: a pilot study
Yang, J., Wu, Y., Zhang, Y., Peng, X., Jiang, C., Zhou, W., Dai, J., Xie, A., Ye, H., & Zheng, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1427649 · Cited by 7
“This reduced diagnostic sensitivity of [ 18 F]FDG is attributed to the low glucose transporter 1 (GLUT-1) expression observed in the SRCC and MAC (23, 24).”
Background
Developing Quality Measures for Diagnostic Radiologists: Part 2
Itri, J. N., Raghavan, K., Patel, S., Broder, J. C., Tierney, S., Gray, D. D., Burleson, J., MacDonald, S. T., & Seidenwurm, D. J. (2018) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2018.05.040 · Cited by 7
Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer.
Soldevilla-Gallardo, I., Medina-Ornelas, S., Villarreal-Garza, C. M., Bargalló‐Rocha, E., Caro-Sánchez, C. H. S., Hernández-Ramírez, R., & Estrada-Lobato, E. (2018) · Europe PMC (PubMed Central) · Cited by 7
Enzyme trafficking and coclustering precede and accurately predict human breast cancer recurrences: an interdisciplinary review
Petty, H. R. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00042.2022 · Cited by 7
β-Configured clickable [ 18 F]FDGs as novel 18 F-fluoroglycosylation tools for PET
Elgland, M., Nordeman, P., Fyrner, T., Antoni, G., Nilsson, K. P. R., & Konradsson, P. (2017) · New Journal of Chemistry · doi:10.1039/c7nj00716g · Cited by 7
Monitoring Early Changes in Tumor Metabolism in Response to Therapy Using Hyperpolarized 13C MRSI in a Preclinical Model of Glioma
Lim, H., Martínez‐Santiesteban, F., Jensen, M. D., Chen, A., Wong, E., & Scholl, T. J. (2020) · Tomography · doi:10.18383/j.tom.2020.00024 · Cited by 7
“This reduces the contrast and effectiveness of (18)F-FDG PET for imaging and quantification of brain tumors that must be confirmed by other means (13, 23, 24).”
Background
Smart solution of severe problems: Radiolabeled nanocarriers for cancer imaging and therapy
Iqbal, Z., Arafa, E. A., Kanwal, Z., & Murtaza, G. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102205 · Cited by 7
Precise monitoring of mesenchymal stem cell homing to injured kidney with an activatable aptamer probe generated by cell-SELEX
Zou, Y., Wen, X., Ling, D., Zhang, D., Lei, L., Zhu, D., Wang, H., Wang, K., Guo, Q., & Nie, H. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.100974 · Cited by 7
Fully automated identification of brain abnormality from whole-body FDG-PET imaging using deep learning-based brain extraction and statistical parametric mapping
Whi, W., Choi, H., Paeng, J. C., Cheon, G. J., Kang, K. W., & Lee, D. S. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00424-0 · Cited by 7
“Background [18F]fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) has been playing a crucial role in tumor imaging [1, 2].”
BackgroundSelf-citation
A roadmap to high‐resolution standard microcoil MAS NMR spectroscopy for metabolomics
Wong, A. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4683 · Cited by 7

Authors: Zhu, A., Lee, D., & Shim, H.
Affiliations: Emory University (US)
Corresponding author: Shim, Hyunsuk
ORCID: Lee, Daniel
Shim, Hyunsuk
Venue: Seminars in Oncology
Publisher: Elsevier BV
Published: 2011-02
Volume: 38
Issue: 1
Pages: 55-69
ISSN: 0093-7754 (ISSN-L)
DOI: 10.1053/j.seminoncol.2010.11.012
PMC: PMC3075495
OpenAlex: W1982620463
Cited by: 368
References: 121
Citations by year: 2026: 16 · 2025: 31 · 2024: 35 · 2023: 24 · 2022: 35 · 2021: 33 · 2020: 38 · 2019: 36 · 2018: 30 · 2017: 26 · 2016: 17 · 2015: 13 · 2014: 11 · 2013: 11 · 2012: 10
FWCI: 8.32
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Seminars in Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P50CA128301)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords: FDG-PET, cancer diagnosis, tumor staging, restaging, treatment response assessment, amino acid analogs, choline PET, tumor glucose metabolism, tumor lipid metabolism, tumor imaging agents
MeSH terms: Choline, Humans, Neoplasm Staging, Neoplasms, Sensitivity and Specificity, Tyrosine, Drug Monitoring, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Molecular Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic Positron Emission Tomography Imaging in Cancer Detection and Therapy Response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks